$MSOS $TLRY $CGC $ACB: Cannabis Reform Holds, but the Sector Splits

In August, we left the cannabis sector facing 274 pages of closing briefs. The government was asking for broader Schedule III treatment. The other designated participants in the administrative proceeding were arguing against it. The market wanted a date. The documents offered a process.

A month later, that distinction remains central. We have not found a new final decision on broader rescheduling in the public DEA docket. What has arrived instead is an appellate order concerning the medical framework already in force, legislation changing part of the hemp timetable, fresh company results and European developments that demand a more differentiated reading.

Cannabis is moving in several directions at once. In the United States, parts of the new framework remain operative while litigation continues. In Germany, commercial growth must now be assessed alongside reimbursement changes and proposed access restrictions. In Canada, differences between producers, distributors, retailers and diversified platforms are becoming harder to ignore.

This next chapter therefore addresses two questions together: how much has the regulatory framework changed, and which companies are showing progress that could survive without the next major Washington headline?

From August’s record to September’s operating reality

Our analysis of the post-hearing briefs explained why counting pages for and against rescheduling is not the same as counting votes. The proceeding is not decided by a majority of participants. What matters is whether the administration can connect the evidence to the statutory requirements and explain a decision that withstands judicial review.

The September 16 check of the DEA’s 2026 proceeding page shows transcripts for the eleven hearing days and procedural orders. A final recommended decision from the administrative law judge is not posted there. That describes the publicly visible record; it does not establish that work has stopped or that an outcome has been agreed privately.

The connection to July matters. In “After the DEA Hearing, the Cannabis Trade Moves Into the Shadows”, we identified courts and tax implementation as possible sources of the next important development. September has produced a concrete event on one of those parallel tracks.

September 9 preserved the present without settling the future

The two federal tracks must remain distinct. The first concerns the measure announced April 23 and published and effective April 28, 2026, placing defined medical categories in Schedule III: FDA-approved products and marijuana covered by qualifying state medical licenses. The second concerns the broader proceeding covering the remaining marijuana. The Federal Register rule controls the first measure’s scope and effective date.

On September 9, the D.C. Circuit denied the request to stay that medical order. The two-page court order, in case 26-1106 and consolidated proceedings, leaves the framework operative while litigation proceeds. It also denies intervention requests while allowing participation as amici.

The significance is limited but concrete. Operators are not facing an immediate suspension under that request. However, denial of a stay is not a final ruling upholding the regulation on the merits. The underlying challenge remains alive. The court document is the decisive primary source here; the linked copy is hosted by a sector publication.

Our economic interpretation is that an immediate disruption to the medical framework has been avoided. It would be premature to convert that into a permanent reduction of every regulatory risk. A company can benefit from operating continuity while remaining exposed to the litigation’s eventual outcome, its own corporate structure and the application of the relevant rules.

Broader rescheduling continues separately. The judge’s recommendation, party exceptions and final agency action are different procedural stages. The DEA hearing rules do not create a certain decision date by adding a fixed number of days to the close of testimony. Repetition on social media does not turn an invented deadline into an official appointment.

Section 280E still matters most economically, but follow it through to cash

The central point of our coverage remains unchanged: Section 280E applies to business activity involving Schedule I or II substances under the conditions in the statute. A classification change can therefore alter deductions for affected activities. It does not make every activity within a group identical, automatically eliminate historical liabilities or resolve tax disputes.

In their April 23 announcement, Treasury and the IRS identified expense allocation for mixed businesses and a transition rule for the taxable year containing the order’s effective date among the subjects of planned guidance. That is different from an automatic refund of all taxes paid in earlier years.

Our check of Internal Revenue Bulletin 2026-38 found no new marijuana-specific provision. This is a bounded verification, not proof that every administrative channel is inactive. Company tax notes, the activities covered and the difference between a taxpayer’s position and a finally determined treatment remain essential.

That distinction often disappears in market discussion. A prospective tax benefit can improve the estimated value of a business. A reduction in actual cash taxes can strengthen its immediate ability to invest or repay debt. A disputed refund claim carries a different risk profile again. Putting all three under a single “cash” label gives readers a misleading picture of financial strength.

The useful questions for U.S. operators are therefore practical: how much activity falls within the changed treatment, which expenses are allocated to it, what benefit reaches cash taxes paid and what uncertainty remains in the notes? For Canadian producers, the economic connection to affected U.S. activities must first be established. Sharing the cannabis label is not sufficient.

Hemp: the delay became law; a durable solution did not

This is one of the clearest changes from our August article. At that point, we were describing Senate action awaiting completion. H.R. 6500 was signed September 2. The White House announcement confirms enactment, while section 2019 of the enrolled legislation contains the hemp provision.

Much of the change previously scheduled for November 12 is postponed until December 11, 2026. The delay is partial: the specifically excluded categories concerning cannabinoids that cannot naturally be produced by the plant remain on the earlier timetable. It should not be described as the cancellation of all restrictions.

For a beverage or other hemp-product business, additional weeks can help with inventory, contracts and distribution planning. They do not automatically support a multiyear investment. For a state-licensed marijuana operator, restrictions on competing hemp products can have a different commercial effect. That asymmetry requires analysis; it is not a universal sector benefit.

Tilray, Organigram and businesses with CBD or beverage activities therefore need product-specific and channel-specific treatment. Even a brand with promising distribution remains exposed to rules governing ingredients, dosage, packaging and the markets it serves. A delay changes the time available. The economics still depend on the model permitted after that time expires.

Banking, licensing and states: the other parts of reform

GAO-26-107498, published in August and publicly released September 8, documents continuing financial-access obstacles, including compliance costs, legal concerns and difficulties with payments and credit. It is not new banking legislation. Nor does the number of institutions filing selected FinCEN reports establish how many maintain ongoing relationships with plant-touching businesses.

A separate issue has reached the Supreme Court’s docket. Peridot Tree, No. 26-343, seeks review of residency preferences in cannabis licensing. The official docket records a September 10 petition, docketing September 15 and a response due October 15. The Court has not yet granted review. Filing the petition does not authorize interstate cannabis shipments.

Illinois provides a more immediate operating example. Its September 10 announcement grants medical licenses to 37 existing adult-use dispensaries. Those are not 37 newly built stores. The change expands permitted activity at locations already in the market.

This is the same principle explored in our spring coverage of state regulation: licensing, patient access, testing and packaging affect everyday economics before a sweeping federal reform resolves the whole system. Comparing multistate operators therefore requires looking at their actual locations. A national rule does not erase differences in prices, competition and operating costs between states.

Germany: a major market becomes a risk that needs better measurement

For months, Europe has been presented as the answer to Canada’s limitations. That remains a relevant business thesis, but September makes its vulnerabilities more visible. Germany is both a market to serve and a healthcare system capable of changing the conditions of access.

The Health Ministry’s guidance states that cannabis flower ceased to qualify for statutory health-insurance reimbursement on July 29. The current section 31 of SGB V retains coverage for other categories, including standardized extracts and specified medicines, subject to statutory conditions. This is not the closure of the entire German medical market.

Separately, the parliamentary proposal concerning prescribing and mail-order supply would impose additional restrictions. On September 15, the minister again called for tighter rules, according to Deutsches Ärzteblatt. Political remarks do not put the proposal into force.

The analytical consequence is that “German revenue” is too broad a category. Flower and extracts, private-pay and reimbursed demand, in-person prescribing and digital access need to be distinguished. Without that breakdown, both optimistic and pessimistic forecasts risk applying their assumptions to the wrong revenue base.

Aurora, Tilray, Canopy, Organigram, High Tide, Village Farms and MediPharm operate different models. Certified production can provide access advantages while still requiring profitable sales. A distributor can expand volumes rapidly while financing more working capital. An extract portfolio can have a different exposure from one concentrated in flower.

Our interpretation remains selective: medical infrastructure retains value, but it does not guarantee future growth. The next quarterly test is how companies absorb changes in demand without sacrificing price, margin or liquidity. Announced capacity should be compared with orders, sales and collections, not merely with the theoretical size of an addressable market.

France and the Netherlands: opportunities with different boundaries

The French government page verified September 14 describes a transition for patients already participating in the experiment, extended until three months after a forthcoming HAS opinion. It does not establish a general commercial opening on October 1. For followers of Tilray and other international suppliers, industrial preparedness is not yet a certain revenue date.

In the Netherlands, the September 9 WODC report describes mostly positive early experiences and broader product variety, but does not yet establish clear attributable effects on health, consumption, safety or neighborhood conditions. Village Farms’ September 15 response is favorable. That commercial participant’s interpretation should be read alongside the public evaluator’s methodological caution.

The distinction directly connects VFF and CRON to the policy framework. Village Farms is already participating in the program; Cronos still needs to complete its planned acquisition of CanAdelaar. The operation of an experiment and the completion of an acquisition are separate tests. Neither justifies describing the Netherlands as a newly unrestricted national cannabis market.

Aurora and Curaleaf: a contest over the medical platform’s value

Aurora’s September 16 business update reaffirms expected sequential growth in revenue and adjusted EBITDA for Q2 FY2027. Safari and international expansion support management’s operating thesis. This is a reaffirmation, not a guidance increase or a new acquisition of Safari.

The test remains the one we established in spring: manufacturing quality and medical reach must turn into results. In Q1 FY2027, Aurora reported C$67.6 million of revenue, C$3.4 million of adjusted EBITDA and a C$5.8 million free-cash-flow outflow. Expected improvement therefore needs confirmation in subsequent accounts rather than being treated as already achieved.

Curaleaf adds a second dimension. Its September 15 letter urges Aurora shareholders to tender and announces a Q&A with Boris Jordan on September 17 at 10:30 a.m. ET. Aurora’s board argues that the offer undervalues the company and transfers bidder-related risks to its shareholders.

These are competing positions from interested parties. The transaction has not closed. The dispute over Aurora’s ATM program also requires a distinction between party requests, company responses and any regulator’s orders. An allegation or application is not itself an order already granted.

The industrial question matters because it crosses the boundary between U.S. cannabis and international platforms. A medical network’s potential value includes licenses, compliant capacity and distribution, as well as volume. Shareholder value also depends on the price and form of consideration, dilution and the risks attached to shares received in exchange.

Continuing coverage: Aurora Stock Hub.

Tilray, Canopy and Cronos: three developments with different implications

Tilray — reducing debt by issuing shares. The filing signed September 14 reports 2,841,650 shares issued in exchange for US$12 million principal of 5.20% convertible notes due June 2027. This is a debt-for-equity exchange, not US$12 million of new cash raised.

That distinction returns TLRY to a recurring theme in our coverage: platform growth also needs to be assessed per share. Removing a liability can improve flexibility while increasing the number of shares participating in future results. Cannabis, distribution and beverages also require separate margin analysis. Tilray Stock Hub.

Canopy — execution includes governance. Canopy has reminded shareholders to vote ahead of the September 25 annual meeting, with a stated proxy deadline of September 23. Its September 8 Australian medical-product expansion adds a commercial development, but is not new quantitative revenue guidance.

For CGC, the test remains whether products and distribution can translate into sustainably better cash performance. A launch can contribute without proving that the turnaround is complete. U.S. exposure requires the same care: structures and economic rights must be read through filings rather than automatically attributing every related operation’s results to the parent. Canopy Stock Hub.

Cronos — the transaction deadline moves again. The CanAdelaar 8-K extends the long-stop date from September 9 to October 15. The amendment is dated September 8 and was filed September 11. It is not a closing confirmation. The September 24 Investor Day, at noon EDT, provides another opportunity to examine strategy and capital allocation.

Financial strength buys time, but capital allocation determines how that time is used. A delay may be manageable for a well-funded buyer without becoming positive operating news: until completion, the asset remains a transaction to execute. Cronos Stock Hub.

High Tide, Organigram, SNDL and Village Farms: the accounts matter

HITI’s September 14 Q3 FY2026 results show C$198.8 million revenue, C$16.2 million adjusted EBITDA and C$7 million free cash flow. C$12.7 million net income includes non-cash effects; the company’s adjusted measure is C$2.2 million. Remexian adds German exposure. Announced exchange discussions about potential U.S. opportunities are not authorization to enter adult-use cannabis.

OGI’s August 20 Sanity integration announcement replaces a performance-based earnout with a fixed obligation. International expansion must therefore be assessed alongside acquisition commitments. The September 30 Investor Session at 4 p.m. ET provides an opportunity to examine integration, margins and capital requirements. Organigram Hub.

SNDL still requires segment-level analysis. Its Q2 2026 release reports C$598.5 million in combined unrestricted cash, marketable securities and investments, including equity-accounted investees. That is not all immediately available cash. Quarterly free cash flow was approximately negative C$6.7 million. The question remains what the platform generates as well as what it owns. SNDL Hub.

VFF brings production and exports into the comparison. Its August 10 results reported US$64 million consolidated sales, US$20.9 million international exports and US$8.9 million operating cash flow. September’s Dutch development concerns the program’s context, not a newly reported quarter.

These figures do not produce an automatic ranking. Fiscal periods and currencies differ, while adjusted EBITDA and free cash flow follow company definitions. They instead help separate four questions: is retail growth profitable; do acquisitions improve returns; does financial wealth support a self-funding operation; and does production expansion meet demand at adequate margins?

The distinction between operating cash and working-capital timing deserves particular attention. A growing distributor may need to fund inventory and receivables before collecting from customers. A producer may add capacity well before reaching utilization targets. Neither circumstance automatically invalidates the strategy, but both can change how much capital shareholders must supply before the strategy delivers its promised return.

MSOS contains companies, not one DEA decision

AdvisorShares’ September 15 holdings show TRLV at 30.85%, CURLF at 27.54% and GTBIF at 16.82%. Together, that is 75.21%, approximately three quarters of the disclosed portfolio. Weights can change, and some exposures use swaps. Cash and collateral entries should not be read as though the fund were a simple collection of ordinary shares.

That concentration makes “how is reform going?” an insufficient question. The performance of those companies matters too. Trulieve now trades as TRLV on the NYSE; historical coverage used TCNNF. Its SEC-filed presentation describes the separation of Harvest activities and the medical operating perimeter associated with the listing. This is a specific corporate case, not an automatic passport for every MSO.

Green Thumb, GTBIF, reported Q2 revenue of US$306.7 million, up 4.6%, while gross margin fell to 45% from 49.9%. Revenue growth can coexist with pressure on product economics. Curaleaf, CURLF, adds its Aurora bid, with transaction-specific risks and capital considerations, to the operating picture.

Our broader coverage also includes Cresco, CRLBF, with US$173 million of Q2 revenue, and Verano, now VRNO, identified as VRNOF in older articles. The Verano filing reports approximately US$218 million revenue and US$51 million adjusted EBITDA, down from about US$66 million a year earlier.

These August reports are operating reference points, not September 16 company announcements. They explain why a potential tax improvement should not obscure price pressure, competition or financing costs. An ETF spreads exposure across names without eliminating common industry problems or the specific weaknesses of its largest holdings.

The extended watchlist belongs in the picture too

Our coverage also includes Auxly, XLY, Cannara, LOVE, and MediPharm Labs, LABS, alongside the better-known Nasdaq names. Their place here reflects different operating models, rather than an attempt to complete a list of symbols.

Auxly’s August 13 Q2 release reported C$45.8 million net revenue and C$14.3 million adjusted EBITDA. July’s 14:1 share consolidation matters for historical per-share comparisons. Cannara’s July 15 results reported C$44.1 million gross cannabis revenue. “Gross” matters: that figure is not directly comparable with revenue reported net of excise taxes.

MediPharm’s August 13 Q2 release reported C$10 million revenue and C$0.9 million adjusted EBITDA, with growth in Germany. Medical specialization does not eliminate scale risk, but it provides a different perspective from general cannabis retail.

AKAN, previously examined in our historical company dossier, remains a reminder that thematic association and operating economics are different. That article examined a transition toward telecommunications and financing risk. It would be inappropriate to recycle it as evidence that Akanda is a current direct beneficiary of Section 280E changes. We are not attributing a new cannabis operating announcement to AKAN or presenting historical float figures as current.

One Canadian regulatory date completes the picture. Health Canada lists October 1 for technical harmonization amendments, including provisions involving cannabis-containing medicines and test kits. This is a previously announced compliance date, not a new legalization measure.

The next dates, and what would actually change the assessment

A constructive scenario requires more than a favorable headline: stability in the medical framework, greater tax clarity, progress in broader rescheduling and businesses converting activity into cash. An intermediate scenario involves uneven progress, different national rules and company results that continue to separate the names. A negative scenario combines litigation, access restrictions and a need for additional capital before expected returns arrive.

We do not assign numerical probabilities to those scenarios. The available documents do not support that precision. The appropriate reason to update the assessment is a completed procedural or operating step and its demonstrated effect on the company concerned.

September’s central point is that the U.S. medical framework has survived a stay request, while the entire cannabis sector has not received an all-clear. Europe offers real business opportunities alongside real access risks. Capital transactions can strengthen companies while changing the economics for each existing share.

This continues the story established in our earlier research: after years of collective promises, cannabis needs to be read company by company. The next DEA decision matters greatly. What each business does while waiting already matters now.

Follow the central Cannabis Stocks Hub for ongoing sector updates and individual company research.

Sources and method. Links throughout the article identify the relevant documents. Company statements, including those of the parties to the Aurora–Curaleaf offer, are attributed to their issuers; economic implications are editorial analysis. Quarterly figures retain their original periods and currencies. No unverified intraday quote or share-price move is used to support the thesis.

Informational and educational content only. This is not investment, legal, tax or medical advice, or a recommendation to buy or sell securities. Cannabis companies face volatility, regulatory change, dilution, liquidity constraints and execution risks. Adjusted measures do not replace accounting results or cash-flow analysis.